Inhibitors of Bruton'S tyrosine kinase
View Patent ↗Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
1. A method of treating a myeloma in a subject comprising administering to a subject in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), having the structure of Formula (A):
wherein:
A is N;
R 1 is phenyl-O-phenyl or phenyl-S-phenyl;
R 2 and R 3 are independently H;
R 4 is L 3 -X-L 4 -G, wherein,
L 3 is optional, and when present is an optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, optionally substituted or unsubstituted alkynyl;
X is optional, and when present is O, —C(═O), S, —S(═O), —S(═O) 2 , —NH, —NR 9 , —NHC(O), —C(O)NH, —NR 9 C(O), —C(O)NR 9 , —S(═O) 2 NH, —NHS(═O) 2 , —S(═O) 2 NR 9 —, —NR 9 S(═O) 2 , —OC(O)NH—, —NHC(O)O—, —OC(O)NR 9 —, —NR 9 C(O)O—, —CH═NO—, —ON═CH—, —NR 10 C(O)NR 10 —, heteroaryl, aryl, —NR 10 C(═NR 11 )NR 10 —, —NR 10 C(═NR 11 )—, —C(═NR 11 )NR 10 —, —OC(═NR 11 )—, or —C(═NR 11 )O—;
L 4 is optional, and when present is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle;
or L 3 , X and L 4 taken together form a nitrogen containing heterocyclic ring;
G is
wherein,
R 6 , R 7 and R 8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl;
each R 9 is independently selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl;
each R 10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or
two R 10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or
R 11 and R 10 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; and
each R 11 is independently selected from H, —S(═O) 2 R 8 , —S(═O) 2 NH 2 , —C(O)R 8 , —CN, —NO 2 , heteroaryl, or heteroalkyl; or pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the myeloma is plasma cell myeloma.
3. The method of claim 1 , wherein the irreversible inhibitor is administered orally.
4. The method of claim 1 , wherein the irreversible Btk inhibitor has the structure:
5. The method of claim 1 wherein L 3 , X and L 4 taken together form a nitrogen containing heterocyclic ring.
6. The method of claim 5 wherein G is
7. The method of claim 5 wherein R 6 , R 7 , and R 8 are each independently H.
8. A method of treating a myeloma in a subject comprising administering to a subject in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk) having the structure of
or a pharmaceutically acceptable salt thereof.